AVID200 is a selective trap of TGFβ1 and TGFβ3 that showed the capacity to enhance the anti-tumor efficacy by inhibiting the growth of syngeneic 4T1 TNBC homograft in immunocompetent host mice.187 A phase I clinical trial of AVID200 revealed that it was safe and well tolerated for patients with advanced solid tumors.208,209. This evidence concerns the gene TGFB1 and neoplasm.